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Abstract
Recent studies have demonstrated that both the potency and breadth of the humoral anti-HIV-1 immune response in
generating neutralizing antibodies (nAbs) against heterologous viruses are significantly enhanced after superinfection by
discordant HIV-1 subtypes, suggesting that repeated exposure of the immune system to highly diverse HIV-1 antigens can
significantly improve anti-HIV-1 immunity. Thus, we investigated whether sequential plasma from these subjects
superinfected with discordant HIV-1 subtypes, who exhibit broad nAbs against heterologous viruses, also neutralize their
discordant early autologous viruses with increasing potency. Comparing the neutralization capacities of sequential plasma
obtained before and after superinfection of 4 subjects to those of matched plasma obtained from 4 singly infected control
subjects, no difference in the increase in neutralization capacity was observed between the two groups (p=0.328). Overall,
a higher increase in neutralization over time was detected in the singly infected patients (mean change in IC50 titer from first
to last plasma sample: 183.4) compared to the superinfected study subjects (mean change in IC50 titer from first to last
plasma sample: 66.5). Analysis of the Breadth-Potency Scores confirmed that there was no significant difference in the
increase in superinfected and singly infected study subjects (p=0.234). These studies suggest that while superinfection by
discordant subtypes induces antibodies with enhanced neutralizing breadth and potency against heterologous viruses, the
potency to neutralize their autologous viruses is not better than those seen in singly infected patients.
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Introduction
The importance of neutralizing antibodies (nAbs) was initially
shown in various non-human primate models, where passive
immunization with nAbs was able to protect against SIV and
SHIV-1 infection [1–8]. Whilst the ability of nAbs to protect
against HIV-1 infection in humans still remains to be defined in
more detail, the emergence of nAbs during the course of HIV-1
infection is a critical element of the host humoral immune
response against the virus [9–13]. Within a few months of HIV-1
infection, nAbs against the autologous virus develop [9–11,14–18].
Anti-HIV-1 nAbs in the infected host are polyclonal and they
target different epitopes on the viral envelope glycoproteins gp120
and gp41 [19–28]. Over the course of acute to chronic infection
the immune response matures, leading to the development of more
potent antibodies that neutralize early autologous virus. In
response to the immune pressure nAbs exert on the virus, escape
mutants appear. As a consequence, the potency of nAbs against
early autologous viruses increases over time until the response
gradually wanes as the virus evolves and recognition of early virus
fades. These well-documented successive waves result in nAbs
from a specific time point being able to neutralize autologous virus
from months earlier, but not concurrent circulating variants [10–
13,29–31]. Whether or not there are distinct patterns of
neutralization of autologous viruses by antibodies from individuals
infected with one (singly infected) or two or more (superinfected)
HIV-1 subtypes remains to be studied. Furthermore, not much is
known on the evolution of nAb responses to early autologous
viruses in patients superinfected with discordant or concordant
HIV-1 subtype strains [32–33].
Superinfection, the concomitant or sequential infection with two
or more genetically distinct HIV-1 strains, was shown to occur
frequently in communities where diverse HIV-1 subtypes co-
circulate and, through reverse transcriptase template switching
between two viral RNAs, can result in the generation of
recombinant virus strains [34–37]. Superinfection provides
a unique opportunity to examine how the host immune response
is affected when challenged by diverse HIV-1 antigens, particu-
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also serve as a natural model for vaccine trial through
immunization by concordant or discordant immungens. Pre-
viously, our lab and others reported that superinfection by
genetically discordant HIV-1 subtypes generated broad and
potent nAb activity against heterologous viruses, increasing both
potency and breadth of the anti-HIV-1 nAb-response [38–39].
This suggested that superinfection strengthens the immune
response against heterologous viruses and that vaccines incorpo-
rating divergent immunogens may induce more broad and potent
nAbs than monovalent ones. However, it remains unknown if
superinfection with discordant HIV-1 subtypes also induces
antibodies in their host that potently neutralize their early
autologous viruses in addition to heterologous nAbs. Therefore,
in order to determine whether antibodies in individuals super-
infected with discordant viruses that potently and broadly
neutralize heterologous viruses also exert potent neutralizing
capacities to their infecting early autologous viruses, we tested the
nAb activities of sequential plasma samples against autologous
pseudotyped viruses generated from the initial and superinfecting
virus variants.
Results
Neutralization Patterns of the Early Autologous Viruses in
Individuals Superinfected with Discordant HIV-1
Subtypes
Two sequential plasma samples from subjects who were
identified to be superinfected with two discordant HIV-1 subtypes
were tested in neutralization assays to determine the pattern and
potency of neutralization of their early autologous viruses. A total
of 4 subjects including CMNYU107, CMNYU6518,
CMNYU129, and CMNYU6544 were studied. HIV-1 pseudo-
viruses of the respective initial and superinfecting virus strains were
generated via PCR of gp120 (HXB2 location 6219–7787) using
plasma that was collected before superinfection and plasma from
the time point of detection of superinfection (Table 1). Each of the
pseudotyped viruses were tested in neutralization assays against
two-fold serial dilutions (1:20–1:2560) of autologous patient
plasma obtained before (first plasma) and after (last plasma)
superinfection (Table 2).
Neutralization of autologous virus from patient
CMNYU107. gp120 sequences of initial virus variants were
amplified from plasma 15 months before superinfection was
detected (Table 1). The six initial variants were genetically
characterized as CRF36_cpx whilst the six superinfecting variants
were defined as subtype G (Figure 1).
In our neutralization studies, the plasma sample obtained before
superinfection (referred to as first plasma) did not achieve 50%
neutralization of the initial or the superinfecting autologous virus
variants (Figure 2A). However, the plasma sample obtained 15
months after superinfection (referred to as last plasma) was able to
achieve 50% neutralization of 5 of the 6 initial variants (variants
2–6) (mean IC50 titer 38) as well as 5 of the 6 superinfecting virus
variants with IC50 titers ranging from 33 to 59 (mean IC50 titer 39)
(Figures 2A and 2B). This increase in neutralization by the plasma
sample obtained 15 months after superinfection was statistically
significant for both initial and superinfecting variants (p=0.0043).
Neutralization of autologous virus from patient
CMNYU6518. Because plasma obtained from this patient prior
to superinfection was exhausted in other studies and because those
studies revealed that variants were epidemiologically related to the
initially infecting variants (subtype CRF36_cpx) from patient
CMNYU107, the same pseudovirus variants were also tested in
neutralization with subsequent plasma from patient
CMNYU6518. The superinfecting variants (n=6) from this
patient (CMNYU6518) were defined as a URF of CRF36_cpx
and CRF01_AE [37] (Figure 1). The neutralization potency of two
sequential plasma samples obtained from the time point of
detection of superinfection (first plasma) and 57 months after
detection of superinfection (last plasma) were determined with the
pseudotyped viruses from this patient (Table 2). Plasma acquired
at the time point of superinfection neutralized only 1 of 6 initial
virus variants, exhibiting an IC50 titer of 21, and 1 of 6
superinfecting variants with an IC50 titer of 19.5 (Figure 3A).
The later plasma sample (obtained 57 months after superinfection)
was able to neutralize all 6 initially-infecting variants, exhibiting
significantly increased IC50 titers of 76–123 (mean IC50: 102,
p=0.0005). Fifty percent neutralization was also reached against
all 6 superinfecting variants using the last plasma sample,
a significant increase from the plasma obtained at time of
detection of superinfection (mean IC50: 82, p=0.0005)
(Figures 3A and 3B).
Neutralization of autologous virus from patient
CMNYU129. gp120 sequences from 6 initially infecting virus
variants were amplified from plasma obtained 9 months before
superinfection was detected (Table 1) and phylogenetically
characterized as CRF02_AG while all the superinfecting variants
were characterized as sub-subtype F2 (Figure 1). Plasma obtained
9 months before superinfection was unable to neutralize the initial
variants. However, this plasma sample achieved 50% neutraliza-
tion against two variants of the superinfecting virus with IC50 titers
of 136 against variant 1 and 152 against variant 2 (Figure 4A). The
last plasma sample, obtained 24 months after superinfection,
neutralized 4 of 6 initial variants (IC50 titers of 49, 58, 212, and
599) and 2 of 6 superinfecting variants (IC50 titers of 230 and 266)
(Figures 4A and 4B). The increase in neutralization of the initial
virus variants by the last plasma sample was significant
(p=0.0183) whilst that of the successive virus variants was not
significant (p=0.839).
Neutralization of autologous virus from patient
CMNYU6544. Initial variants (n=6) amplified from patient
plasma nine months before detection of superinfection (Table 1)
were genetically characterized as a URF of CRF02_AG/F2 while
the superinfecting variants were characterized as CRF02_AG with
,15% distance from the initial variants (Figure 1). The
neutralization studies revealed that the first plasma (collected nine
months before detection of superinfection) was able to achieve
50% neutralization of all 6 initial variants (mean IC50 titer: 98),
whilst none of the superinfecting virus variants were neutralized
(Figure 5A). The last plasma sample (obtained 41 months after
detection of superinfection) exhibited IC50 titers of 65–88 against
the 6 initial variants (mean IC50 titer: 75). This last plasma also
achieved 50% neutralization of 3 of the 6 superinfecting variants
(variant 2, 3 and 6) at IC50 titers of 19, 28 and 43, respectively
(Figures 5A and 5B).
Neutralization Patterns of the Early Autologous Viruses in
Individuals with Single HIV-1 Subtype Infection
Two sequential plasma samples from patients from the same
cohort chronically infected with HIV-1 who were identified to be
singly infected with one subtype virus were also tested in
neutralization assays to determine the pattern and potency of
neutralization of their early autologous viruses. A total of 4 subjects
including CMNYU133, CMNYU179, CMNYU153 and
CMNYU6542 were studied; gp120s of the infecting HIV-1
variants were amplified (HXB2 location 6219–7787) from their
plasma samples at two different time points, matching the timing
HIV-1 Superinfection and Autologous Neutralization
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were used to produce pseudotyped viruses and tested in
neutralization assays with two-fold serial dilutions (1:20–1:2560)
of autologous patient plasma (Table 2).
Neutralization of autologous virus from patient
CMNYU133. The virus variants were amplified from an early
(variants 1–4) and a late plasma sample (variants 5–8) (Table 1).
Phylogenetic analysis of the gp120 sequences of all the variants of
CMNYU133 revealed clustering with subtype F2 (Figure 1). The
first plasma achieved 50% neutralization of its contemporaneous
virus variants 1–4 with IC50 values of 334–777. A non-significant
decline in IC50 levels against virus variants 1–4 was detected in the
Table 1. Data of HIV-1 viruses infecting study subjects.
Subject ID Isolated at study month Subtype
Superinfected
CMNYU107 Initial virus 6 CRF36_cpx
Successive virus 21 G
CMNYU6518 Initial virus 0 CRF36_cpx
Successive virus 15 01_AE- CRF36_cpx URF
CMNYU129 Initial virus 0 CRF02_AG
Successive virus 9 F2
CMNYU6544 Initial virus 3 CRF02_AG-F2 URF
Successive virus 12 CRF02_AG
Singly-infected
CMNYU133 Initial virus 0 F2
Successive virus 15 F2
CMNYU179 Initial virus 0 CRF02_AG
Successive virus 15 CRF02_AG
CMNYU153 Initial virus 0 H
Successive virus 30 H
CMNYU6542 Initial virus 3 CRF02_AG
Successive virus 12 CRF02_AG
doi:10.1371/journal.pone.0038989.t001
Table 2. Data of plasma samples from patients used for neutralization.
Subject ID
Plasma from study
month
Duration of study
(months) CD4 count DCD4
Superinfected
CMNYU107 First plasma 9 27 269 285
Last plasma 36 184
CMNYU6518 First plasma 3 57 370 19
Last plasma 60 389
CMNYU129 First plasma 0 33 603 2266
Last plasma 33 337
CMNYU6544 First plasma 3 50 266 23
Last plasma 53 289
Singly-infected
CMNYU133 First plasma 0 21 923 2331
Last plasma 21 592
CMNYU179 First plasma 0 77 515 2111
Last plasma 77 404
CMNYU153 First plasma 6 24 290 211
Last plasma 30 279
CMNYU6542 First plasma 3 50 709 2110
Last plasma 53 599
doi:10.1371/journal.pone.0038989.t002
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(Figure 6A). Pseudovirus variants 5–8 could not be neutralized by
the first plasma sample. However, the last plasma, obtained 21
months later, was able to achieve 50% neutralization of variants
5–8 (mean IC50 titer: 633). This was a significant increase in
neutralization (p=0.00673) (Figure 6A).
Neutralization of autologous virus from patient
CMNYU179. The virus variants were amplified from an early
plasma sample (variants 1–5) and a late plasma sample (variants 6–
9) (Table 1). Phylogenetically, the gp120 sequence of all variants
clustered with CRF02_AG (Figure 1). The first plasma sample
achieved 50% neutralization of variant 4 (Figure 6B). The last
Figure 1. Phylogenetic analysis of gp120 sequences (HXB2 location 6219–7787) amplified from patient plasma samples and used to
construct pseudotyped viruses. Most reference and study subject sequences have been omitted for clarity. Reference sequences are highlighted
by black circles.
doi:10.1371/journal.pone.0038989.g001
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virus variants (variants 1–5) (IC50 titers ranging from 23 to 114,
significant increase, p=0.00184) and all virus variants that were
isolated from a later time point plasma (variants 6–9) (IC50 titers
ranging from 41 to 80, significant increase, p=0.00673)
(Figure 6B).
Neutralization of autologous virus from patient
CMNYU153. HIV-1 viruses pseudotyped with gp120 of 8
variants infecting study subject CMNYU153 were amplified (early
variants 1–4, later variants 5–8) (Table 1). Phylogenetic analysis
revealed clustering of all the variants with subtype H (Figure 1).
The first plasma was unable to achieve 50% neutralization of the 8
virus variants (Figure 6C). However, the last plasma sample,
obtained 24 months after the first plasma, neutralized variants 1–4
(mean IC50 titer: 56, p=0.00673) as well as variants 5–8 (mean
IC50 titer: 38), a significant increase from the first plasma
(p=0.00673) (Figure 6C).
Neutralization of autologous virus from patient
CMNYU6542. HIV-1 viruses pseudotyped with gp120 se-
quences of 8 variants infecting study subject CMNYU6542 were
amplified (early variants 1–4, later variants 5–8) (Table 1).
Phylogenetically, all 8 variants clustered with CRF02_AG
(Figure 1). The first plasma sample was able to achieve 50%
neutralization of variants 2, 5, and 6, exhibiting IC50 titers of 13–
27. The last plasma sample, obtained 50 months after the first
plasma, exhibited a significantly increased neutralization of all the
variants tested (variants 1–4: mean IC50 titer: 419, p=0.00673;
variants 5–8: mean IC50 titer: 548, p=0.00673) (Figure 6D).
Comparison of Neutralization Sensitivity of Plasma
Derived gp120 Pseudotyped Viruses Versus PBMC
Isolated Viruses from Patients
The pseudoviruses used in our neutralization studies described
above bear the gp120 portion of the envelope derived from the
study subjects’ plasma. Therefore the gp120-gp41 envelopes are
chimeras that may not display the same epitopes as the native
envelope would in its natural form. Anti-gp41 antibodies may be
present in the patient plasma that might not recognize the gp41
used for the pseudoviruses. We therefore questioned whether the
gp120 pseudotyped viruses used in our studies would similarly be
neutralized like the viruses isolated from patient PBMCs. For this,
we isolated the early autologous viruses from two patients
(CMNYU107 [superinfected] and CMNYU179 [singly infected]),
using the same time points that were used for pseudovirus
construction, and compared their neutralization sensitivity with
those of the corresponding pseudotyped viruses. In study subject
CMNYU107, just as the first plasma sample (obtained 12 months
before superinfection) did not neutralize the pseudoviruses, it also
did not neutralize the PBMC derived viruses. Furthermore, the
last plasma sample acquired 15 months after superinfection)
similarly neutralized both the initial and superinfecting pseudo-
virus variants as well as the PBMC derived initial and super-
infecting viruses (Figures 2 and 7A). In patient CMNYU179 the
first plasma sample did not neutralize the PBMC derived viruses
but neutralized 3 of 9 pseudovirus variants at low level. The last
plasma sample of study subject CMNYU179 was able to neutralize
all pseudovirus variants and the PBMC derived viruses (Figures 6B
Figure 2. Neutralization of autologous virus variants by serially-diluted plasma obtained from study subject CMNYU107. A: Mean
IC50 values with standard deviation of initial and superinfecting virus variants. B: Titration of last plasma against initial (mean of initial variants in red)
and successive virus variants (mean of successive variants in blue). Only variants that reached 50% neutralization are included.
doi:10.1371/journal.pone.0038989.g002
Figure 3. Neutralization of autologous virus variants by serially-diluted plasma obtained from study subject CMNYU6518. A: Mean
IC50 values with standard deviation of initial and superinfecting virus variants. B: Titration of last plasma against initial (mean of initial variants in red)
and successive virus variants (mean of successive variants in blue). Only variants that reached 50% neutralization are included.
doi:10.1371/journal.pone.0038989.g003
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pseudoviruses studied are representative of the gp160 envelopes in
the natural viruses.
Comparison of IC50 Titers of Superinfected and Singly
Infected Study Subjects against Autologous Pseudovirus
Variants
Neutralization against the initial virus variants increased over
time in 3 of the 4 superinfected subjects (range 4-16-fold increase)
(Table 3, and Figures 2, 3, 4, 5) and in 3 of the 4 singly infected
patients (range 4-35-fold increase) (Table 3, and Figure 6) whilst
IC50 titers against the successive virus variants increased over time
in all the superinfected (range 2-7-fold increase) (Table 3, and
Figures 2, 3, 4, 5) and singly infected study subjects (range 4-40-
fold increase) (Table 3, and Figure 6). Whilst the increase in
neutralization from first to last plasma sample in the superinfected
study subjects (mean change in IC50 titer from first to last plasma
sample: 66.5) was lower than in the singly infected patients (mean
change in IC50 titer from first to last plasma sample: 183.4), no
significant difference in the increase in neutralization capacity
against their early autologous viruses was observed between the
two groups (p=0.328).
Determination of Breadth-Potency Scores
Breadth-Potency scores (B-P Scores) were calculated in order
to be able to compare the neutralization capacity of the singly
and superinfected patients’ plasma. The B-P score was
computed by averaging all obtained x values, which were
calculated by setting x=log10(IC50) for the available IC50s and
by setting x=0 for viruses that did not neutralize. This is
equivalent to multiplying the fraction of viruses neutralized by
the mean of the available IC50s, which in turn is the area under
the B-P curve [40]. First, the neutralization breadth and
potency of the respective first and last plasma samples against
the initial pseudoviruses were analyzed. These pseudoviruses
were called ‘‘initial virus variants’’ in the superinfected study
group and ‘‘initial virus variants 1–4 or 50 in the singly infected
control subjects. For superinfected and singly-infected study
subjects, these initial pseudoviruses were generated from plasma
that was isolated an average of 0.25 months before the first
plasma sample that was used for neutralizations and an average
of 42.6 months before the last plasma sample used for
neutralization. There was no significant difference between
singly and superinfected study subjects in the time elapsed
between plasma samples used for neutralization and the
generation of pseudoviruses. The mean change of B-P Scores
in the initial virus variants between the last and the first plasma
sample tested was 1.112 in the superinfected study subjects
(range from 20.110 to 1.784) and 1.280 in the singly infected
subjects (range from 20.278 to 2.300). No significant difference
in change of B-P Score was observed between singly and
superinfected patients (p=0.886) (Figure 8). Next, the neutral-
ization breadth and potency of the respective first and last
Figure 4. Neutralization of autologous virus variants by serially-diluted plasma obtained from study subject CMNYU129. A: Mean
IC50 values with standard deviation of initial and superinfecting virus variants. B: Titration of last plasma against initial (mean of initial variants in red)
and successive virus variants (mean of successive variants in blue). Only variants that reached 50% neutralization are included.
doi:10.1371/journal.pone.0038989.g004
Figure 5. Neutralization of autologous virus variants by serially-diluted plasma obtained from study subject CMNYU6544. A: Mean
IC50 values with standard deviation of initial and superinfecting virus variants. B: Titration of last plasma against initial (mean of initial variants in red)
and successive virus variants (mean of successive variants in blue). Only variants that reached 50% neutralization are included.
doi:10.1371/journal.pone.0038989.g005
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These pseudoviruses were called ‘‘successive virus variants’’ in
the superinfected study group and ‘‘initial virus variants 5–8 or
90 in the singly infected control subjects. These later
pseudoviruses were generated from plasma that was isolated
an average of 13.125 months after the first plasma sample that
was used for neutralizations and an average of 29.25 months
before the last plasma sample that was used for neutralization.
There was no significant difference between singly and super-
infected study subjects in the time elapsed between plasma
samples used for neutralization and the generation of pseudo-
viruses. The mean change of B-P Score between the last and
the first plasma sample tested was 0.965 in the superinfected
study subjects (range from 0.078 to 1.680) and 1.687 in the
singly infected subjects (range from 1.097 to 2.113). No
significant difference in change of B-P Score was observed
between singly and superinfected patients (p=0.2) (Figure 8).
Correlation between the Heterologous and Autologous
Neutralization Capacity of Superinfected and Singly
Infected Study Subjects
Previously, our lab reported that HIV-1 superinfection by
genetically distinct strains correlates with significantly increased
potency and breadth of the nAb response against heterologous
viruses [38]. The IC50 titers of super- and singly infected
patients’ plasma against 6 heterologous primary isolates were
determined, including Bx08 (subtype B), CMNYU102
Figure 6. Neutralization of autologous virus variants by serially-diluted plasma obtained from singly infected patients. Mean IC50
values with standard deviation of A: study subject CMNYU133. B: study subject CMNYU179. C: study subject CMNYU153. D: study subject
CMNYU6542.
doi:10.1371/journal.pone.0038989.g006
Figure 7. Neutralization of autologous PBMC derived virus by serially-diluted plasma. Mean IC50 values with standard deviation of A:
study subject CMNYU107 (superinfected). B: study subject CMNYU179 (singly infected).
doi:10.1371/journal.pone.0038989.g007
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(CRF02_AG), CMNYU161 (CRF02_AG), and CMNYU6491
(subtype G) [38]. In 3 of 4 superinfected patients, plasma
samples collected after superinfection (referred to as last plasma)
exhibited significantly increased IC50 titers relative to plasma
samples obtained before superinfection (referred to as first
plasma). The mean increase in neutralization against heterolo-
gous viruses from first to last plasma sample in superinfected
patients CMNYU107, CMNYU6518 and CMNYU6544 was
55-fold, 12-fold, and 25-fold, respectively (Table 4) [38]. In
comparison, the same samples tested against their respective
autologous pseudoviruses on average only achieved a 4-8-fold
increase in neutralization (Table 4 and Figures 2, 3, 4, 5).
Whilst the singly-infected control subjects exhibited no signifi-
cant changes in their magnitude of neutralization against
heterologous viruses over the study period, a significant increase
Table 3. Comparison of mean IC50 titers of superinfected and singly infected study subjects against autologous pseudovirus
variants.
Initial variants Successive variants
Subject ID Plasma sample Mean IC50 Fold increase Mean IC50 Fold increase
Superinfected
CMNYU107 First plasma 10 4 10 4
Last plasma 38* 39*
CMNYU6518 First plasma 12 9 12 7
Last plasma 102* 82*
CMNYU129 First plasma 10 16 55 2
Last plasma 156* 89
CMNYU6544 First plasma 98 0 10 2
Last plasma 75 20*
Singly-infected
CMNYU133 First plasma 456 0 16 40
Last plasma 252 633*
CMNYU179 First plasma 12 4 16 4
Last plasma 53* 61*
CMNYU153 First plasma 10 6 10 4
Last plasma 56* 38*
CMNYU6542 First plasma 12 35 15 37
Last plasma 419* 548*
doi:10.1371/journal.pone.0038989.t003
Figure 8. Mean change in B-P Scores in superinfected and singly infected study subjects. Circles and squares represent superinfected and
singly infected samples, respectively. Horizontal lines indicate mean values. Red colour indicates the initial virus variants, whilst colour blue indicates
the later virus variants.
doi:10.1371/journal.pone.0038989.g008
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patients’ plasma tested against their respective autologous
pseudoviruses was detected (mean increase from first to last
plasma sample in IC50 titers ranging from 2-37-fold) (Table 4
and Figure 6). These results clearly demonstrate that while
superinfection with discordant HIV-1 subtypes enhances the
ability to neutralize heterologous viruses, it does not enhance
the neutralization of early autologous viruses.
Correlation between Viral Load, CD4 Counts and
Neutralization Patterns
While the mean CD4 count of the initial plasma samples
obtained from superinfected study subjects (mean CD4 count:
377 cells/ml) was lower than the initial plasma samples from the
singly infected control group (mean CD4 count: 609 cells/ml), this
difference was not statistically significant (p=0.2). In the final
plasma samples from the singly infected control subjects (mean
CD4 count: 469 cells/ml) and the superinfected subjects (mean
CD4 count: 300 cells/ml), the mean CD4 counts were also not
significantly different (p=0.2). The mean change in CD4 count
for the control group from the first to the last plasma sample was –
141 cells/ml, while that of the superinfected group was –77 cells/
ml. These changes were not significantly different (p=0.343)
(Table 2). For example, the study duration was similar for
superinfected patient CMNYU107 (27 months) and the singly
infected patient CMNYU153 (24 months). Both subjects started
with comparable CD4 counts (269 and 290 cells/ml, respectively)
and experienced a slight drop in CD4 levels over the study period
(–85 and –11 cells/ml, respectively). The neutralization pattern of
CMNYU107 and CMNYU153 was also comparable, with the
initial plasma sample being unable to achieve 50% neutralization
of the autologous virus variants and the final plasma sample
reaching mean IC50 titers of 47 and 38, respectively. Thus, in both
subjects the drop in CD4 counts did not impair the neutralizing
antibody response. CMNYU133 was the only patient where
a decrease in IC50 titers against the initial virus variants was
observed over time – in this patient the CD4 counts also decreased
substantially over the study period (–331 cells/ml). However, in
this study subject the nAb response against the later virus variants
was increasing over the study period, therefore the drop in CD4
counts cannot be made accountable for the decrease in IC50 titers
against initial variants. Viral load data for some of the first and all
of the last plasma samples has previously been reported and no
significant difference was detected between the superinfected and
singly infected groups [38].
Discussion
Previously, we and others reported enhanced nAb responses in
individuals superinfected with discordant HIV-1 subtype strains
against several HIV-1 heterologous viruses [38–39]. Because these
previous studies suggested that reinfection with a discordant
subtype enhances the patient’s immune response to generate
antibodies that neutralize heterologous viruses, we hypothesized
that the potency to neutralize early autologous viruses in the
superinfected patients would also be increased compared to the
singly infected control subjects. Thus, in this current study,
sequential plasma samples of the 4 patients superinfected with
discordant HIV-1 subtype strains we previously studied were
tested for their potency and breadth to neutralize viruses
pseudotyped with autologous gp120. In comparison, the neutral-
ization capacity of matched plasma from 4 singly infected study
Table 4. Comparison of mean IC50 titers of superinfected and singly infected study subjects against heterologous and autologous
viruses.
Subject ID Plasma sample
Mean IC50 against
heterologous viruses
(n=6) Fold increase
Mean IC50 against
autologous pseudoviruses
(n=8–12) Fold increase
Superinfected
CMNYU107 First plasma 10 55 10 4
Last plasma 550* 38*
CMNYU6518 First plasma 38 12 12 8
Last plasma 459* 92*
CMNYU129 First plasma 10 0 32 4
Last plasma 10 123
CMNYU6544 First plasma 10 25 54 0
Last plasma 251* 47
Singly-infected
CMNYU133 First plasma 21 0 236 2
Last plasma 10 442*
CMNYU179 First plasma 10 0 14 4
Last plasma 10 57*
CMNYU153 First plasma 13 0 10 5
Last plasma 15 47*
CMNYU6542 First plasma 16 0 13 37
Last plasma 12 483*
IC50 titers against heterologous viruses were taken from the following publication: Powell, R. L., T. Kinge, and P. N. Nyambi. 2010. Infection by discordant strains of HIV-1
markedly enhances the neutralizing antibody response against heterologous virus.
doi:10.1371/journal.pone.0038989.t004
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sured. We observed that the increase in neutralization from first to
last plasma sample in the superinfected study subjects (mean
change in IC50 titer from first to last plasma sample: 66.5) was
lower than in the singly infected patients (mean change in IC50
titer from first to last plasma sample: 183.4). However, the
difference between the two groups was not significant (p=0.328).
Similarly, the calculation of Breadth-Potency Scores confirmed
that there was no significant difference in the increase in
superinfected and singly infected study subjects (p=0.234) from
first to last plasma sample used for neutralization. Therefore, as
illustrated in Table 4, increased potency and breadth to neutralize
heterologous viruses by the superinfected patient’s plasma did not
translate into increased potency to neutralize early autologous
viruses compared to the singly infected study subjects.
It is intriguing to note that while superinfection by discordant
HIV-1 subtypes helps to boost the humoral immune response
against heterologous viruses [38], it does not boost the response
against its early autologous viruses. Previous studies have
demonstrated that different HIV-1 subtype strains share conserved
antigenic epitopes while also harboring epitopes that are unique to
them [41–51]. Therefore, the possibility exists that distinct
antigenic epitopes from the discordant HIV-1 subtypes infecting
these patients broaden the immune response to different viruses. In
that case the superinfecting virus may deviate the focus of the
immune response from more conserved epitopes as well as reduce
the immune pressure on the initially infecting virus strain. This is
supported in part by the longitudinal analysis presented here and
by others revealing an increased immune response to autologous
virus over time in singly infected patients [10–11,29–30]. Though
not significant, overall the sequential plasma from the singly
infected patients tested in this study exhibited a higher neutral-
ization capacity (mean change in IC50 titer from first to last plasma
sample: 183.4) to their early autologous viruses compared to those
from the superinfected patients (mean change in IC50 titer from
first to last plasma sample: 66.5) (Table 3).
It could be argued that the lack of a better enhancement of the
neutralization capacity in the superinfected patients to their early
autologous viruses compared to the singly infected patients could
be due to a weakened immune system caused by the superinfecting
virus. It is important to note that though the patients studied were
in their chronic phase of infection, they were all asymptomatic,
had been infected with HIV for more than 3 years, and the mean
CD4 counts for the superinfected (346 cells/ml) versus the singly
infected patients (506 cells/ml) were similar. This suggests that the
state of their immune systems were comparable and not weak.
Also, if the immune system of the superinfected patients were
weaker, the sequential plasma from these same patients would not
have exhibited the robust neutralization capacity against heterol-
ogous viruses as demonstrated in our previous studies [38]. It is,
however, certain that the immune system during acute infection is
stronger than during chronic infection. Thus, studies that would
examine such responses during acute infection are warranted.
Whether or not superinfection by discordant subtypes would
induce a better humoral immune response to its early autologous
viruses compared to superinfection by concordant virus subtypes
remains to be studied as it would have several implications for
vaccine design and strategies. As an example of a potential
implication in a therapeutic vaccine strategy, the present results
would suggest that challenge of an HIV-1 positive patient with an
immunogen genetically divergent from the HIV-1 strain already
infecting this patient might lead to deviation of the autologous
immune response away from the infecting virus and as a conse-
quence may lead to even faster disease progression. Furthermore,
the fact that these superinfected patients do not exhibit an
enhanced potency to neutralize their early autologous virus might
have implications in disease progression. If the immune response
becomes less focused on the initial virus as a result of immune
stimulation from a different reinfecting virus, the initial virus might
replicate in the host uncontrolled over a period of time. This
increase in virus replication of the initial virus would possibly result
in further immune stimulation to its epitopes and may then result
in deviation of the response to the superinfecting virus - also giving
rise to a higher replication of the reinfecting virus. This possible
cyclical chain of events might then lead to faster disease
progression. However, such studies to examine the impact of
superinfection, evolution of viral replication, viral load, nAb
patterns, and disease progression need to be carefully examined.
While some studies have revealed a rapid disease progression in
some patients superinfected with discordant subtypes [16,52], the
number of patients studied are few and studies that examine
superinfection and disease progression still remain sparse and
incomplete [33,53–55].
The nAb responses against autologous pseudoviruses represent-
ing different variants from the patients at each time point were not
always uniform, given the genetic variability of the quasispecies
(Figures 2, 3, 4, 5, 6). Further study will focus on the sequence
analysis of the initial and superinfecting virus variants and factors
such as insertions and deletions, point mutations, glycan-shielding,
and in some cases the emergence of new recombinant strains
within the superinfected patients that might contribute to viral
escape from neutralization or a gradual switch of nAb responses to
eptiopes on the variants due to antigenic stimulation by a different
variant or a recombinant strain [10–11,29–31].
Overall, the increased breadth and potency of the nAb response
against heterologous viruses by sequential plasma from patients
superinfected with discordant HIV-1 subtypes previously reported
by us [38] did not correspond with an enhanced potency to
neutralize early autologous viruses. While the mechanisms behind
this observation remain to be investigated, the results demonstrat-
ed here suggest that although antibodies present in superinfected
patients may be potent in neutralizing heterologous viruses, their
lack of a significantly enhanced neutralizing activity against their
autologous viruses does not confer advantages in virus control in
the superinfected patients compared to singly infected patients.
Because the number of subjects studied may be small, further
studies involving larger cohorts of patients superinfected with
discordant subtype viruses are warranted to monitor the de-
velopment of neutralizing antibodies and responses to autologous
viruses.
Materials and Methods
Ethics Statement
The study was approved by the New York University School of
Medicine Institutional Review Board and by the National Ethical
Review Board in Cameroon. All volunteers signed written
approved informed consent forms prior to participating in the
study.
Study Subject Data
The blood samples analyzed in this study were collected in
calendar years 2001–2008 in Yaounde, Cameroon, at 3 to 6
month intervals from a cohort of HIV+, chronically infected
individuals. This cohort has been described extensively in our
previously published work [37–38,56]. The subjects of interest to
the present study were chronically infected with HIV-1 and later
determined to be superinfected with discordant HIV-1 subtypes
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CMNYU6544. All cohort study subjects were antiretroviral drug-
naı ¨ve. The subjects were selected based on their identification as
superinfected at an interim study time point and their HIV-1
strains were classified in the C1C2 region of env as: CMNYU107:
CRF36_cpx and subtype G; CMNYU6518: two CRF01_AE/
CRF36_cpx URFs possessing inter-subsubtype (,12%) genetic
distance from one another; CMNYU129: CRF02_AG and
subtype F2; CMNYU6544: CRF02_AG/F2 URF and
CRF02_AG [37] (Table 1). The CD4 counts ranged from 134
to 603 cells/ml (mean 346 cells/ml) (Table 2). The time intervals of
the plasma samples used for neutralization are presented in
Table 2. From this same cohort, a total of 4 individuals identified
as singly infected (with one subtype) were also studied and included
CMNYU133 (subtype F2), CMNYU179 (CRF02_AG),
CMNYU153 (subtype H), and CMNYU6542 (CRF02_AG) [38]
(Table 1). The CD4 counts ranged from 204 to 923 cells/ml (mean
506 cells/ml) (Table 2). There were no significant differences in
study duration or change in CD4 T cell count (DCD4) over the
study period between the superinfected group and the singly
infected control group (Table 2).
RNA Extraction and RT-PCR Amplification of gp120
Viral RNA from patient plasma was extracted using the
QIAamp Viral RNA Mini kit (Qiagen Inc, Valencia, CA)
according to the manufacturer’s instructions. Two microliters of
eluted RNA was used for reverse transcriptase polymerase chain
reaction (RT-PCR) using the Superscript One-Step RT-PCR for
Long Templates kit (Invitrogen, Carlsbad, CA), using primers
EnvA (59-GGCTTAGGCATCTCCTATGGCAGGAAGAA-39)
and gp120OUT (59-GCARCCCCAAAKYCCTAGG-39). The
amplification conditions were as follows: one cycle at 50uC for
30 minutes and 94uC for 2.5 minutes, followed by 50 cycles at
94uC for 15 seconds, 50uC for 30 seconds and 68uC for 2.5
minutes, ending with a single extension cycle at 72uC for 7
minutes. Two microliters of first-round product was then used in
a nested PCR using the Platinum PCR SuperMix High Fidelity
system (Invitrogen, Carlsbad, CA), using the primers EnvB (59-
AGAAAGAGCAGAAGACAGTGGCA-39) and gp120IN (59-
CGTCAGCGTYATTGACGCYGC-39). For the second-round
PCR, amplification conditions were: one cycle at 94uC for 2
minutes, followed by 35 cycles at 94uC for 15 seconds, 50uC for 30
seconds and 68uC for 1 minute. Two microliters of each PCR
product was run on a 1% agarose gel to confirm amplification of
the expected 1636bp fragment (HXB2 location 6202–7838) and
the absence of any 1
st round products.
Cloning, Sequencing and Phylogenetic Analysis
PCR products were cloned into the Topo TA cloning vector
and plasmids were transformed into chemically competent E.coli
cells according to manufacturer’s recommendations (Invitrogen,
Carlsbad, CA). A total of 24 positive colonies, selected by
Kanamycin resistance and X-Gal blue-white screening, were
cultured in 3 ml LB broth plus 10 mg/ml Kanamycin overnight.
Plasmids were purified using the QIAprep Spin Miniprep kit
(Qiagen Inc, Valencia, CA). Positive clones were sequenced at the
59 and 39 end with the universal T3 and T7 primers. To obtain the
full gp120 sequence, primer walking was performed. Individual
sequence fragments were assembled using the Pregap and Gap
programs from the Staden software package [57] and open gp120
reading frames were confirmed using the Sequence Locator tool
provided by the Los Alamos HIV Sequence Database (http://
www.hiv.lanl.gov/content/sequence/LOCATE/locate.html).
Construction of Virus Pseudotyped with each Study
Stubject’s HIV-1 gp120
Topo-cloned gp120 sequences with open reading frames were
used for creating env-expression vectors. Topo-cloned gp120 and
primers PseudoAmpF (59-GAAGAGCAGAAGACAGTCGC-
GATGAAAGTGAAGGGGATAC-39) and PseudoAmpR (59-
GTTATTGACGCCGCGCCCATAGTC-
GACCCTGCTGCTCCTAAGAAC-39) were used to amplify
gp120 out of the vector while inserting NruI and SalI restriction
sites, using the PCR SuperMix High Fidelity system, according to
manufacturer’s instructions (Invitrogen, Carlsbad, CA). The
amplification conditions were: one cycle at 94uC for 2 minutes,
followed by 45 cycles at 94uC for 15 seconds, 50uC for 30 seconds
and 68uC for 1.5 minutes. Two microliters of PCR product was
run on a 1% agarose gel to verify correct amplification. The
remaining product was then purified using the Qiaquick PCR
Purification Kit according to manufacturer’s instructions (Qiagen,
Valencia, CA), and subjected to a 2 hr NruI/SalI digest, followed
by an overnight DpnI digest, according to manufacturer’s protocol
(New England Biosciences, Ipswich, MA). Digested amplicon was
then purified as above, quantified, and ligated into the p1930
vector using the T4 DNA Ligase kit according to manufacturer’s
protocol (Invitrogen, Carlsbad, CA). The p1930 vector is a variant
of the p166 vector (pcDNA3.1 backbone; kindly donated by Dr.
Abraham Pinter), which expresses a subtype C HIV-1 envelope
under the control of a CMV promoter. p1930 was created using
Quickchange Mutagenesis (Stratagene, La Jolla, CA), which
inserted an NruI site and a SalI site on the 59 and 39 ends,
respectively, of the p166 gp120. Before ligation of the gp120
amplicon into p1930, p1930 was subjected to NruI/SalI digest
followed by overnight treatment with Calf Intestinal Alkaline
Phosphatase (CIAP) and purification as described above. Chem-
ically competent XL-1 Blue cells were transformed with the
ligation reaction according to manufacturer’s protocol (Invitrogen,
Carlsbad, CA), and plated on Ampicillin-LB plates. Colonies were
screened by colony PCR for correctly ligated gp120 insert, and
sequenced as described above with primers RP-1770 (59-
GGCTTGCCTTAGGCATCTCC-39) and RP-1773 (59-
GCTGTTGATCCTTTAGGTATC-39) with primer walking.
Sequence analysis was performed and sequences were checked
for open reading frames as described above. Positive vectors were
transformed into Stbl2 cells according to manufacturer’s protocol
(Invitrogen, Carlsbad, CA), plated, and then one colony was
picked and used to inoculate a 50 mL of LB-Ampicillin broth for
overnight culture. Vector was purified from this culture using the
HiSpeed Plasmid Midi kit according to manufacturer’s instruc-
tions (Qiagen, Valencia, CA).
Cells
TZM-bl cells were used in neutralization assays (see below at
‘‘Titration and Neutralization assay of pseudotyped viruses’’ and
[58–59]). These cells are maintained in DMEM supplemented
with 10% fetal bovine serum, 1% glutamine, and 2% penicillin
plus streptomycin (TZM-DMEM). The cultures were kept at 37uC
in a 5%-CO2 humidified incubator.
Pseudovirus Production
Purified vector was used to co-transfect 293T cells with the
Q23Denv HIV-1 backbone plasmid using Fugene 6, according to
manufacturer’s protocol (Roche, Manheim, Germany) [60]. After
48 hours, supernatant was removed from cells, and spun at
3000 rpm for 10 min. The FBS concentration was brought up to
20% and the pseudovirus was stored at 280uC until use.
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Pseudovirus was titrated in a 96-well plate, using 200 ml of viral
supernatant in the first well and setting up a 2-fold dilution series
with DMEM media along the row. Per well, 10 000 TZMbl cells
were added in a volume of 100 ml, and DEAE-dextran was added
to each well at a final concentration of 12.5 mg/ml. The plates
were incubated for 72 h at 37uC. Then luminescence was
measured using the Bright Glo Reagent (Bright-Glo Luciferase
Assay System, Promega, Madison, Wisconsin) on a Lumimark Plus
System microplate reader (Bio-Rad Laboratories, Hercules, CA) as
previously described [38]. The titrated pseudoviruses were then
tested in neutralization assays with TZM-bl cells, as previously
described [58–59]. Briefly, 1:20–1:2560 diluted heat-inactivated
plasma from each patient at each time point and a fixed dilution of
each patient’s corresponding autologous pseudovirus were mixed
in equal volumes (50 ml each) and incubated for 1 hour at 37uC;
10 000 cells in 100 ml of DMEM media containing 25 mg/ml
DEAE-dextran (final concentration 12.5 mg/ml) was added to
each well, and cells were incubated for 48 hours as previously
described [38]. To measure the background luminescence, wells
with cells only (no pseudovirus, no plasma) were included. As
control, virus-only wells (cells infected with pseudovirus, no
plasma) were also tested. Cells were lysed using the Bright Glo
Reagent (Bright-Glo Luciferase Assay System, Promega, Madison,
Wisconsin) and relative light units (RLU) were measured on
a Lumimark Plus System microplate reader (Bio-Rad Laborato-
ries, Hercules, CA) as previously described [38].
Statistical Analysis, Calculation of Percent Neutralization,
IC50 Titer, and Breadth-Potency Scores
Neutralization was assessed in duplicates, and experiments were
repeated a minimum of two times. Percent neutralization was
determined by dividing the mean RLU for each set of duplicates
by the mean RLU in the appropriate replicates of virus-only
control wells, after subtraction of the cells-only background from
all RLU values. Mean IC50 values were determined by identifying
the adjacent dilutions being above and below the 50% readout.
The assay readouts for the dilutions above and below 50%
neutralization were joined with a straight line and the position
where the line crossed the 50% readout was taken as IC50 titer
[61]. Statistical significance of overall pairwise neutralization
comparisons was determined using the Mantel-Cox logrank test.
The Wilcoxon rank sum test was used to compare the CD4 counts
and viral load data between singly and superinfected patient
groups. Breadth-Potency (B-P) scores, a measure that accounts for
both the simultaneous potency and the breadth of a tested plasma
sample, were determined as follows: A Breadth-Potency (B-P)
curve was plotted where y = the fraction of viruses whose IC50
exceeds x, where x=log10 (IC50). At x=0 the height is y=
fraction of viruses in the panel for which an IC50 was achieved, i.e.
the ‘‘fraction neutralized’’. The B-P score represents the area
under the B-P curve, an area that increases with both breadth and
potency. It can be shown that this area – the B-P Score – can be
computed by simply averaging all x values obtained by setting
x=log10(IC50) for the available IC50s and by setting x=0 for
viruses that did not neutralize. This is equivalent to multiplying the
fraction of viruses neutralized by the mean of the available IC50s
[40].
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